| Document |
Document Title |
|
WO/2023/244920A2 |
Described herein are compositions and kits comprising recombinant adeno- associated viruses (rAAVs) with increased transduction enrichment in the brain, heart, or brain and heart. The rAAV compositions described herein encapsidate a tran...
|
|
WO/2023/244843A1 |
The present disclosure relates to the methods and compositions for enhancing productivity or yield in fermentation. The methods include culturing host cells at a high pH to increase oxygen uptake as well as a higher yield and productivit...
|
|
WO/2023/245050A2 |
The disclosure provides compositions and methods for generating a population of engineered immune cells, e.g., T cells, that express recombinant or synthetic T cell receptors and are depleted of cells that express endogenous T cell recep...
|
|
WO/2023/242769A1 |
IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fu...
|
|
WO/2023/243495A1 |
Provided is a method capable of expressing and activating the function of a G-protein conjugated receptor (GPCR). A method for expressing a GPCR polypeptide comprises expressing, in a cell, a GPCR polypeptide comprising an amino acid seq...
|
|
WO/2023/241653A1 |
The present invention relates to an IL-2 mutant, a fusion protein containing the IL-2 mutant, a nucleic acid encoding the IL-2 mutant or the fusion protein containing the IL-2 mutant, a vector and a host cell containing the nucleic acid,...
|
|
WO/2023/242559A1 |
The invention relates to antibacterial protein complexes derived from nuclease bacteriocins, and to their production and use, and to related products having an antibacterial surface. The complexes comprise a nuclease bacteriocin polypept...
|
|
WO/2023/244044A1 |
One aspect relates to a modified coronavirus spike antigen protein and uses thereof. It was confirmed that a spike antigen protein of coronavirus, according to one aspect, exhibited suppression of cell membrane fusion ability and improve...
|
|
WO/2023/241697A1 |
The present disclosure provides a cell (e.g., AMD-associated cell, such as RPE) comprising a polypeptide capable of reversing phase separation and/or preventing the formation of drusen, a polynucleotide encoding the polypeptide, and/or a...
|
|
WO/2023/245169A1 |
New antimicrobial combinations for use against pathogenic microbes are described, along with methods of making and using the same. The present disclosure is also related to and describes novel combinations of antimicrobial peptides such ...
|
|
WO/2023/242844A1 |
The present invention provides a therapeutic agent selected from (a) a mitochondria targeted-insulin-like growth factor- 1 receptor (mitoIGFIR) agonist; and (b) a nucleic acid molecule encoding for the expression of mitoIGFIR or a portio...
|
|
WO/2023/242176A1 |
Fusion proteins and methods for conditionally fine-tuning transposase protein stability and activity for clinical applications are provided herein
|
|
WO/2023/244001A1 |
The present invention provides a fusion protein vaccine composition by the identification of immune-active domains (sites or segments) of Rv2299c protein, the removal of unnecessary sites or the selection of only necessary portions, and ...
|
|
WO/2023/242425A1 |
The present disclosure provides for circular RNA (circRNA) compositions and methods purification and use of the same. In particular, the disclosure relates to compositions and methods of making and using circRNA comprising one or more ap...
|
|
WO/2023/242273A1 |
The present invention relates to the animal-free production of casein proteins for human consumption by expression of such proteins in fungal cells. The invention relates to fungal cells modified for the production of caseins, and to met...
|
|
WO/2023/244510A2 |
Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are fusion proteins specific to t...
|
|
WO/2023/244511A2 |
Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are chimeric antigen receptors (C...
|
|
WO/2023/242271A1 |
The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.
|
|
WO/2023/241522A1 |
Provided are a T cell receptor targeting a KRAS G12V mutant polypeptide and a use thereof. The T cell receptor molecule specifically targets a KRAS G12V mutation; a CDR3 sequence of an α chain variable domain thereof contains CAVRDIEGAG...
|
|
WO/2023/244760A1 |
Disclosed herein are protein-RNA display constructs that couple a protein of interest to its encoding mRNA. An example protein-RNA display construct includes a first nucleotide portion including an RNA that forms hairpin structures; a se...
|
|
WO/2023/242138A1 |
The present invention relates to engineered immune cells expressing synthetic receptors that activate expression of a response element encoding a stimulator of interferon genes (STING) protein, and their use in methods for treating disea...
|
|
WO/2023/245125A2 |
Provided herein are compositions and methods for producing pyridine-based macrocyclic peptides.
|
|
WO/2023/245057A2 |
Disclosures herein are directed to polypeptide probes that may be used to detect transthyretin (TTR) oligomers or fibrils in patient samples obtained from subjects with wildtype and mutant TTR alleles. Also provided are methods of using ...
|
|
WO/2023/245097A2 |
Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules, or antigen-binding fragments thereof, that immunospecifically bind to human programmed cell death protein- 1 (hPD-1), and immunoconjugates comp...
|
|
WO/2023/245168A1 |
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metab...
|
|
WO/2023/245131A1 |
The present disclosure provides compositions and vectors comprising a transgene(s) encoding more than one isoform of Crumbs homologue-1 (CRB1) (e.g., CRB1-A and CRB1-B), and compositions thereof, for use in the treatment or prevention of...
|
|
WO/2023/244499A2 |
Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are bi-specific fusion proteins a...
|
|
WO/2023/242436A1 |
The present invention relates to synthetic and/or recombinant consensus allergens and to their use as allergy vaccines in particular in the treatment of peach-cypress allergy, in the form of an allergy vaccine comprising a consensus alle...
|
|
WO/2023/244517A1 |
Interleukin-2 (IL-2) prodrugs useful for treatment and prevention of cell proliferation and cancer in a patient are provided.
|
|
WO/2023/244470A1 |
ROS signal upregulates surface CALR and promotes macrophage-HSC interactions, safeguarding the development of stem cells that are stressed or damaged. Described herein are methods of controlling hematopoiesis, e.g., reducing hematopoiesi...
|
|
WO/2023/244547A1 |
Antibodies with improved affinity for integrin avB8 and uses thereof are provided.
|
|
WO/2023/244269A1 |
Plant breeding and engineering has relied primarily on Mendelian genetics or recombinant techniques. The disclosure relates to novel maize plants, seeds and compositions, as well as improvements to maize plant breeding and methods for cr...
|
|
WO/2023/244997A1 |
The present disclosure provides methods, compositions, and systems or kits for treating cancer, promoting an anti-cancer response, and/or increasing anti-cancer immunity. Particularly, the disclosure relates to liposomal antibiotic formu...
|
|
WO/2023/240322A1 |
The present invention pertains to the purification of soluble complement receptor proteins and variants thereof by hydrophobic interaction chromatography (HIC) using a chromatographic material with a particle size of less than 60 µm.
|
|
WO/2023/245100A1 |
Engineered, non-naturally occurring antimicrobial NCR13 variant peptides (NVPs), or agriculturally acceptable salts thereof, are described, along with methods of making and using the same. The present disclosure is also related to and de...
|
|
WO/2023/245160A1 |
The present disclosure provides a method of enhancing an immune response in a subject in need thereof, including administering an effective amount of an antigen with an immune modulator to the subject, wherein the immune modulator is a q...
|
|
WO/2023/245139A2 |
The presently claimed and described technology provides vaccine compositions comprising at least two mutant-calreticulin (CALR)-peptides, wherein the at least two peptides have overlapping sequences and methods for administration of the ...
|
|
WO/2023/245128A1 |
An engineered, non-naturally occurring antimicrobial peptide, or an agriculturally acceptable salt thereof comprising, consisting essentially of, or consisting of, an amino acid sequence set forth in SEQ ID NO: 1 is described, along with...
|
|
WO/2023/242633A2 |
Provided herein are recombinant adeno-associated virus (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins.
|
|
WO/2023/238961A1 |
The present invention provides a pH-responsive carrier for nucleic acid delivery to cells or tissues, comprising a combination of a cationic polymer having a side chain containing a primary amine and a block copolymer represented by the ...
|
|
WO/2023/239736A1 |
Provided herein is a recombinant cell comprising a deletion of a gene encoding a transporter associated with antigen processing (TAP) protein and mutations in the CD3 epsilon gene and an HLA-A gene. Also provided are systems and methods ...
|
|
WO/2023/239226A1 |
Provided are a fusion protein comprising an anti-TIGIT antibody binding specifically to TIGIT or an antigen-binding fragment thereof and interleuckin-15 (IL-15), and a medicinal use of the fusion protein.
|
|
WO/2023/237541A1 |
We identified several novel δΤ-cell and γΤ-cell receptor chains mediating anti-tumour or anti-infective responses as well as methods for identifying same.
|
|
WO/2023/240077A1 |
The disclosure provides compositions and methods for the treatment and/or prevention of sickle cell disease.
|
|
WO/2023/237051A1 |
Provided is a LIGHT mutein and a LTβR binding LIGHT mutein, and it also provides a related polynucleotide, an isolated vector, a host cell, and a pharmaceutical composition. Further, provided is the use of the LIGHT mutein or the isolat...
|
|
WO/2023/235921A1 |
Provided herein are methods for the selection or directed evolution of proteins for the engineering of proteins having desired traits. Provided are methods for selecting variants (such as detergent-stable variants) of a protein of intere...
|
|
WO/2023/240182A1 |
The application provides modified immune effector cells wherein a Lysine Demethylase 4A (KDM4A) gene or gene product is modified in the cell so that the expression and/or function of KDM4A in the cell is reduced or eliminated. The applic...
|
|
WO/2023/236822A1 |
Disclosed are development and use of an H5N6 avian influenza broad-spectrum vaccine. Provided are preparation methods for a recombinant protein vaccine, an inactivated vaccine and a nucleic acid vaccine, and use thereof. Experiments show...
|
|
WO/2023/235918A1 |
A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dos...
|
|
WO/2023/240247A2 |
The present disclosure is directed, in part, to saxiphilin proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, and methods of detecting toxin in samples. In some embodiments, the toxin i...
|
